No worries. And yeah, that FY23 result is definitely a bit deceptive because of the massive non-cash one off expense. Makes it look like costs blew out last year when in reality they actually shrunk quite a bit as a percentage of sales. At the rate they are going it really shouldn't be difficult for them to be breakeven or profitable this financial year. They appear to have very good operating leverage so a bit of scale is all they really need (and clearly they are definitely getting that scale!)
- Forums
- ASX - By Stock
- EYE
- Ann: USA Sales Update
Ann: USA Sales Update, page-51
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.64M |
Open | High | Low | Value | Volume |
16.0¢ | 16.0¢ | 15.5¢ | $14.31K | 92.01K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 148500 | 15.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.0¢ | 124195 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 148500 | 0.150 |
8 | 558724 | 0.145 |
11 | 450030 | 0.140 |
2 | 14500 | 0.135 |
6 | 75850 | 0.130 |
Price($) | Vol. | No. |
---|---|---|
0.160 | 124195 | 4 |
0.165 | 119997 | 2 |
0.170 | 200000 | 3 |
0.175 | 100000 | 1 |
0.180 | 100000 | 1 |
Last trade - 12.02pm 13/11/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online